Why Did Warren Buffett Buy Amazon Stock?
When investors think of tech stocks in Warren Buffett’s portfolio,…
Sell
25
BCYC Quote, Financials, Valuation and Earnings
Last price:
$7.25
Seasonality move
:
19.79%
Day range:
$7.11 - $7.50
52-week range:
$6.10 - $28.67
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
18.22x
P/B ratio:
0.68x
Volume:
145.8K
Avg. volume:
273.7K
1-year change:
-64.78%
Market cap:
$500.7M
Revenue:
$35.3M
EPS (TTM):
-$3.14
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BCYC
Bicycle Therapeutics PLC
|
$8.7M | -$0.81 | 0.73% | -20.58% | $26.27 |
|
ADAP
Adaptimmune Therapeutics PLC
|
$6.6M | -$0.17 | -91.39% | -8.33% | $1.58 |
|
AUTL
Autolus Therapeutics PLC
|
$2M | -$0.25 | -80.39% | -10.73% | $9.86 |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | $17.94 |
|
MREO
Mereo BioPharma Group PLC
|
$15.9M | -$0.01 | -100% | -87.66% | $7.64 |
|
NCNA
NuCana PLC
|
-- | -$0.01 | -- | -99.69% | $104.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BCYC
Bicycle Therapeutics PLC
|
$7.23 | $26.27 | $500.7M | -- | $0.00 | 0% | 18.22x |
|
ADAP
Adaptimmune Therapeutics PLC
|
$0.24 | $1.58 | $64.2M | -- | $0.00 | 0% | 0.35x |
|
AUTL
Autolus Therapeutics PLC
|
$2.21 | $9.86 | $588.2M | -- | $0.00 | 0% | -- |
|
BDRX
Biodexa Pharmaceuticals PLC
|
$0.92 | $17.94 | $4.6M | -- | $0.00 | 0% | 0.96x |
|
MREO
Mereo BioPharma Group PLC
|
$2.74 | $7.64 | $435.7M | -- | $0.00 | 0% | -- |
|
NCNA
NuCana PLC
|
$0.09 | $104.00 | $538.5K | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BCYC
Bicycle Therapeutics PLC
|
-- | 1.351 | -- | 14.57x |
|
ADAP
Adaptimmune Therapeutics PLC
|
-211.44% | 3.737 | 50.03% | 1.57x |
|
AUTL
Autolus Therapeutics PLC
|
-- | 2.244 | -- | 8.74x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | 2.381 | -- | 1.20x |
|
MREO
Mereo BioPharma Group PLC
|
-- | -0.685 | -- | -- |
|
NCNA
NuCana PLC
|
-- | -3.655 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BCYC
Bicycle Therapeutics PLC
|
-- | -$70M | -27.79% | -28.27% | -619.32% | -$87M |
|
ADAP
Adaptimmune Therapeutics PLC
|
$6.4M | -$44.1M | -107.36% | -199.63% | -619.47% | -$67.8M |
|
AUTL
Autolus Therapeutics PLC
|
-$9M | -$65.2M | -49.92% | -49.92% | -643.43% | -$83.8M |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
MREO
Mereo BioPharma Group PLC
|
-- | -$11M | -- | -- | -- | -$8.6M |
|
NCNA
NuCana PLC
|
-- | -$3.5M | -- | -- | -- | -$4M |
Bicycle Therapeutics PLC vs. Competitors
-
Which has Higher Returns BCYC or ADAP?
Adaptimmune Therapeutics PLC has a net margin of -608.94% compared to Bicycle Therapeutics PLC's net margin of -653.18%. Bicycle Therapeutics PLC's return on equity of -28.27% beat Adaptimmune Therapeutics PLC's return on equity of -199.63%.
Company Gross Margin Earnings Per Share Invested Capital BCYCBicycle Therapeutics PLC-- -$0.88 $740.3M ADAPAdaptimmune Therapeutics PLC87.93% -$0.18 -$12M -
What do Analysts Say About BCYC or ADAP?
Bicycle Therapeutics PLC has a consensus price target of $26.27, signalling upside risk potential of 263.39%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $1.58 which suggests that it could grow by 550.27%. Given that Adaptimmune Therapeutics PLC has higher upside potential than Bicycle Therapeutics PLC, analysts believe Adaptimmune Therapeutics PLC is more attractive than Bicycle Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings BCYCBicycle Therapeutics PLC5 3 0 ADAPAdaptimmune Therapeutics PLC3 3 0 -
Is BCYC or ADAP More Risky?
Bicycle Therapeutics PLC has a beta of 1.462, which suggesting that the stock is 46.161% more volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.243, suggesting its more volatile than the S&P 500 by 124.255%.
-
Which is a Better Dividend Stock BCYC or ADAP?
Bicycle Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicycle Therapeutics PLC pays -- of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCYC or ADAP?
Bicycle Therapeutics PLC quarterly revenues are $10M, which are larger than Adaptimmune Therapeutics PLC quarterly revenues of $7.3M. Bicycle Therapeutics PLC's net income of -$60.8M is lower than Adaptimmune Therapeutics PLC's net income of -$47.6M. Notably, Bicycle Therapeutics PLC's price-to-earnings ratio is -- while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicycle Therapeutics PLC is 18.22x versus 0.35x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCYCBicycle Therapeutics PLC18.22x -- $10M -$60.8M ADAPAdaptimmune Therapeutics PLC0.35x -- $7.3M -$47.6M
-
Which has Higher Returns BCYC or AUTL?
Autolus Therapeutics PLC has a net margin of -608.94% compared to Bicycle Therapeutics PLC's net margin of -781.13%. Bicycle Therapeutics PLC's return on equity of -28.27% beat Autolus Therapeutics PLC's return on equity of -49.92%.
Company Gross Margin Earnings Per Share Invested Capital BCYCBicycle Therapeutics PLC-- -$0.88 $740.3M AUTLAutolus Therapeutics PLC-99.86% -$0.26 $371.1M -
What do Analysts Say About BCYC or AUTL?
Bicycle Therapeutics PLC has a consensus price target of $26.27, signalling upside risk potential of 263.39%. On the other hand Autolus Therapeutics PLC has an analysts' consensus of $9.86 which suggests that it could grow by 345.95%. Given that Autolus Therapeutics PLC has higher upside potential than Bicycle Therapeutics PLC, analysts believe Autolus Therapeutics PLC is more attractive than Bicycle Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings BCYCBicycle Therapeutics PLC5 3 0 AUTLAutolus Therapeutics PLC8 0 0 -
Is BCYC or AUTL More Risky?
Bicycle Therapeutics PLC has a beta of 1.462, which suggesting that the stock is 46.161% more volatile than S&P 500. In comparison Autolus Therapeutics PLC has a beta of 1.756, suggesting its more volatile than the S&P 500 by 75.594%.
-
Which is a Better Dividend Stock BCYC or AUTL?
Bicycle Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicycle Therapeutics PLC pays -- of its earnings as a dividend. Autolus Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCYC or AUTL?
Bicycle Therapeutics PLC quarterly revenues are $10M, which are larger than Autolus Therapeutics PLC quarterly revenues of $9M. Bicycle Therapeutics PLC's net income of -$60.8M is higher than Autolus Therapeutics PLC's net income of -$70.2M. Notably, Bicycle Therapeutics PLC's price-to-earnings ratio is -- while Autolus Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicycle Therapeutics PLC is 18.22x versus -- for Autolus Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCYCBicycle Therapeutics PLC18.22x -- $10M -$60.8M AUTLAutolus Therapeutics PLC-- -- $9M -$70.2M
-
Which has Higher Returns BCYC or BDRX?
Biodexa Pharmaceuticals PLC has a net margin of -608.94% compared to Bicycle Therapeutics PLC's net margin of --. Bicycle Therapeutics PLC's return on equity of -28.27% beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital BCYCBicycle Therapeutics PLC-- -$0.88 $740.3M BDRXBiodexa Pharmaceuticals PLC-- -- $6M -
What do Analysts Say About BCYC or BDRX?
Bicycle Therapeutics PLC has a consensus price target of $26.27, signalling upside risk potential of 263.39%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.94 which suggests that it could grow by 1849.58%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Bicycle Therapeutics PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Bicycle Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings BCYCBicycle Therapeutics PLC5 3 0 BDRXBiodexa Pharmaceuticals PLC1 0 0 -
Is BCYC or BDRX More Risky?
Bicycle Therapeutics PLC has a beta of 1.462, which suggesting that the stock is 46.161% more volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.210, suggesting its more volatile than the S&P 500 by 21.022%.
-
Which is a Better Dividend Stock BCYC or BDRX?
Bicycle Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicycle Therapeutics PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCYC or BDRX?
Bicycle Therapeutics PLC quarterly revenues are $10M, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Bicycle Therapeutics PLC's net income of -$60.8M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Bicycle Therapeutics PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicycle Therapeutics PLC is 18.22x versus 0.96x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCYCBicycle Therapeutics PLC18.22x -- $10M -$60.8M BDRXBiodexa Pharmaceuticals PLC0.96x -- -- --
-
Which has Higher Returns BCYC or MREO?
Mereo BioPharma Group PLC has a net margin of -608.94% compared to Bicycle Therapeutics PLC's net margin of --. Bicycle Therapeutics PLC's return on equity of -28.27% beat Mereo BioPharma Group PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BCYCBicycle Therapeutics PLC-- -$0.88 $740.3M MREOMereo BioPharma Group PLC-- -$0.10 -- -
What do Analysts Say About BCYC or MREO?
Bicycle Therapeutics PLC has a consensus price target of $26.27, signalling upside risk potential of 263.39%. On the other hand Mereo BioPharma Group PLC has an analysts' consensus of $7.64 which suggests that it could grow by 179%. Given that Bicycle Therapeutics PLC has higher upside potential than Mereo BioPharma Group PLC, analysts believe Bicycle Therapeutics PLC is more attractive than Mereo BioPharma Group PLC.
Company Buy Ratings Hold Ratings Sell Ratings BCYCBicycle Therapeutics PLC5 3 0 MREOMereo BioPharma Group PLC6 0 0 -
Is BCYC or MREO More Risky?
Bicycle Therapeutics PLC has a beta of 1.462, which suggesting that the stock is 46.161% more volatile than S&P 500. In comparison Mereo BioPharma Group PLC has a beta of 0.409, suggesting its less volatile than the S&P 500 by 59.15%.
-
Which is a Better Dividend Stock BCYC or MREO?
Bicycle Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mereo BioPharma Group PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicycle Therapeutics PLC pays -- of its earnings as a dividend. Mereo BioPharma Group PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCYC or MREO?
Bicycle Therapeutics PLC quarterly revenues are $10M, which are larger than Mereo BioPharma Group PLC quarterly revenues of --. Bicycle Therapeutics PLC's net income of -$60.8M is lower than Mereo BioPharma Group PLC's net income of -$12.9M. Notably, Bicycle Therapeutics PLC's price-to-earnings ratio is -- while Mereo BioPharma Group PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicycle Therapeutics PLC is 18.22x versus -- for Mereo BioPharma Group PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCYCBicycle Therapeutics PLC18.22x -- $10M -$60.8M MREOMereo BioPharma Group PLC-- -- -- -$12.9M
-
Which has Higher Returns BCYC or NCNA?
NuCana PLC has a net margin of -608.94% compared to Bicycle Therapeutics PLC's net margin of --. Bicycle Therapeutics PLC's return on equity of -28.27% beat NuCana PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BCYCBicycle Therapeutics PLC-- -$0.88 $740.3M NCNANuCana PLC-- -$0.63 -- -
What do Analysts Say About BCYC or NCNA?
Bicycle Therapeutics PLC has a consensus price target of $26.27, signalling upside risk potential of 263.39%. On the other hand NuCana PLC has an analysts' consensus of $104.00 which suggests that it could grow by 116885.38%. Given that NuCana PLC has higher upside potential than Bicycle Therapeutics PLC, analysts believe NuCana PLC is more attractive than Bicycle Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings BCYCBicycle Therapeutics PLC5 3 0 NCNANuCana PLC0 1 0 -
Is BCYC or NCNA More Risky?
Bicycle Therapeutics PLC has a beta of 1.462, which suggesting that the stock is 46.161% more volatile than S&P 500. In comparison NuCana PLC has a beta of 1.240, suggesting its more volatile than the S&P 500 by 23.98%.
-
Which is a Better Dividend Stock BCYC or NCNA?
Bicycle Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicycle Therapeutics PLC pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCYC or NCNA?
Bicycle Therapeutics PLC quarterly revenues are $10M, which are larger than NuCana PLC quarterly revenues of --. Bicycle Therapeutics PLC's net income of -$60.8M is lower than NuCana PLC's net income of -$3.1M. Notably, Bicycle Therapeutics PLC's price-to-earnings ratio is -- while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicycle Therapeutics PLC is 18.22x versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCYCBicycle Therapeutics PLC18.22x -- $10M -$60.8M NCNANuCana PLC-- -- -- -$3.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will RocketLab Stock Be In 5 Years?
Rocket Lab (NASDAQ: RKLB) closed recently at around $30 per share,…
Is MO dividend Worth It?
Altria Group (NYSE: MO) is paying investors $1.02 a share…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 41x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
88
CDTX alert for Jun 24
Cidara Therapeutics [CDTX] is up 9.01% over the past day.
Sell
46
HIMS alert for Jun 24
Hims & Hers Health [HIMS] is up 3.19% over the past day.
Buy
67
WGS alert for Jun 24
GeneDx Holdings [WGS] is up 8.2% over the past day.
